Ameningococcal with no clear treatment for frequent reoccurrence and malignant diagnosis.
Find out which protein is closely linked to meningeal malignancy.
Implication of the possibility of new treatment of meningococcal in the use of inhibitors.
A team led by Shinhyuk Kang, a professor of neurosurgery at Korea University Anam Hospital (Professor Shinhyuk Kang, Professor Kyungjae Park, and Professor Seokin Park of the Department of Biochemistry and Molecular Biology) found the key proteins that contribute to the development of meninges and presented the possibility of a new treatment for intractable meningesuscular mening. A meningeal tumor is a tumor that occurs in the lining of the brain and spinal cord, and is usually a benign tumor that is easier to treat surgically.However, in the case of malignant diagnosis or benign tumors, recurrence after malignant surgery is not enough for surgery, radiation, and chemotherapy. The study confirmed that a protein called FoxM1 exists in meningeal cells and is closely related to malignantness of tumors, and analyzed the tissues of 101 patients diagnosed with meningitis, and found that the increase in the protein contributes to the recurrence and malignantization of meninges. This was noted by cell-based research and animal testing that FoxM1 inhibition limits the proliferation of malignant meningioma. This suggests that the protein could be used as a biomarker for early diagnosis of meningococcal malignancy, and would be a new target for treatment. “Although more research is needed, the findings are meaningful in that they have set viable goals,” Professor Shinhyuk Kang said. “We hope that future collaborative research with bio-pharmaceuticals will help them develop drugs that can be used for clinical patients and validate their treatment effects.”